novo nordisk glp-1 GoodRx, team to make meds affordable Novo Nordisk Finds Medicare Patients

2026 is the year in which the long-term themes, the true drivers of sustainable success for the burgeoning landscape of obesity treatment, prescription medicines and beyond, become apparent

The GLP-1 market is expected to hit $200 billion by 2031, according to a new study.

Background Alcohol use disorder (AUD) affects nearly half a billion people globally and is associated with significant physical and psychiatric comorbidities

If the clinician determines Microdose isn't right for you, they may recommend a different protocol your monthly billing only changes if your clinician switches you to a different compound

Learn about eligibility, deadlines, and how to file a claim.

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had come to rely on compounded versions is increasingly uncertain.